>
>
Kidney Cancer Drugs Market – By Cancer Type (Renal Cell, Transitional Cell, Wilms Tumor), Therapy (Immunotherapy, Chemotherapy), Drug Class (Mabs, Angiogenesis & mTOR Inhibitors), Route of Administration, Distribution Channel & Global Forecast (2024 – 2032)
Download Free PDF

Kidney Cancer Drugs Market
Get a free sample of this reportGet a free sample of this report Kidney Cancer Drugs Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2023
Companies covered: 15
Tables & Figures: 181
Countries covered: 23
Pages: 110
Download Free PDF
Kidney Cancer Drugs Market Size
Kidney Cancer Drugs Market size was valued at USD 6.2 billion in 2023 and is expected to exhibit growth at a CAGR of 5.6% from 2024 – 2032. High market growth can be attributed to the ongoing advancements in treatment modalities, increasing incidence of kidney cancer, rising healthcare expenditure, and expanding pipeline of novel therapeutics, among other contributing factors.
Moreover, kidney cancer incidence has been steadily increasing globally due to factors such as aging populations, lifestyle changes (e.g., smoking, obesity), and environmental exposures. For instance, according to the American Society of Clinical Oncology (ASCO), in 2023, approximately 81,800 individuals in the U.S. (52,360 men and 29,440 women) were diagnosed with kidney cancer. As the prevalence of kidney cancer rises, there is a growing demand for effective treatment options, driving the growth of the kidney cancer drugs market.
Furthermore, increasing healthcare expenditure, particularly in developed countries, supports greater access to advanced or rapid diagnostics tools, treatment options, and supportive care services for kidney cancer patients. Higher healthcare spending translates into increased demand for kidney cancer drugs, driving market growth. Additionally, expanding access to healthcare in emerging economies contributes to market expansion in those regions.
Kidney cancer drugs refer to medications and therapies used in the treatment of kidney cancer, also known as renal cell carcinoma (RCC) or renal cell adenocarcinoma. These drugs are designed to target cancer cells, inhibit their growth, and/or enhance the body's immune response against the cancer.
Kidney Cancer Drugs Market Trends
The market is experiencing several notable trends that are shaping its growth and development. Factors such as continuous innovations in diagnosis and monitoring, increased focus on personalized medicine, expansion of indications and combination therapies, and growing demand for integrated artificial intelligence in healthcare and machine learning, among other factors are propelling the industry growth.
Kidney Cancer Drugs Market Analysis
Based on cancer type, the market is categorized into renal cell carcinoma (RCC), transitional cell cancer, Wilms tumor, and renal sarcoma. The renal cell carcinoma (RCC) generated the highest revenue of USD 5.4 billion in 2023.
Based on therapy, the kidney cancer drugs market is classified into targeted therapy, immunotherapy, chemotherapy, and other therapies. The targeted therapy segment dominated the market in 2023 with a market share of 53.6%.
Based on drug class, the kidney cancer drugs market is classified into angiogenesis inhibitors, monoclonal antibodies, mTOR inhibitors, cytokine immunotherapy (IL-2), and other drug classes. The angiogenesis inhibitors segment is anticipated the highest market share of 51.4% in 2023.
Based on route of administration, the kidney cancer drugs market is classified into oral, intravenous, and subcutaneous. The oral segment dominated the market and is expected to grow at a pace of 5.6% CAGR between 2024 – 2032.
Based on distribution channel, the kidney cancer drugs market is segmented into hospital pharmacy, brick and mortar, and e-commerce. The hospital pharmacy segment dominated the market in 2023 and is anticipated to reach USD 6.3 billion by 2032.
North America kidney cancer drugs market accounted for USD 2.3 billion market revenue in 2023 and is anticipated to grow at CAGR of 5.3% between 2024 – 2032 period.
The U.S. held a dominant position in the kidney cancer drugs market, with a revenue of USD 2.2 billion in 2023.
Germany kidney cancer drugs market is projected to grow remarkably in the coming years.
Japan holds a dominant position in the Asia Pacific kidney cancer drugs market.
Kidney Cancer Drugs Market Share
The kidney cancer drugs industry is led by major pharmaceutical companies like Pfizer Inc., Novartis AG, and Bayer AG, offering a range of innovative treatments such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. These companies invest heavily in research and development to address unmet medical needs and expand treatment options for kidney cancer patients. Emerging biotech firms are also making strides with promising drug candidates, capitalizing on advancements in precision medicine. With the global rise in kidney cancer cases, demand for effective treatments is increasing, driving significant growth and competition among market players, ultimately leading to improved patient outcomes.
Kidney Cancer Drugs Market Companies
Prominent players operating in the kidney cancer drugs industry include:
Kidney Cancer Drugs Industry News:
The kidney cancer drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:
Click here to Buy Section of this Report
Market, By Cancer Type
Market, By Therapy
Market, By Drug Class
Market, By Route of Administration
Market, By Distribution Channel
The above information is provided for the following regions and countries: